New therapy aims to ease fear of cancer return for lung patients and partners

NCT ID NCT07588347

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new program called ADAPT, which is a type of talk therapy for lung cancer patients and their spouses. The goal is to help both partners feel less afraid of the cancer coming back. About 72 couples will try the program during chemotherapy or radiation and answer questionnaires to see if it helps.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 72 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

May 2026

An estimate. Start dates often move.

Expected to finish

Jun 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

20 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria Patients: * Diagnosis of primary lung cancer confirmed by pathological examination. * Age ≥ 22 years for men and ≥ 20 years for women (legal marriage age in China). * Have undergone lung cancer surgery and are scheduled to receive the first round of radiotherapy and/or chemotherapy treatment * Fear of Cancer Recurrence Inventory-Short Form (FCRI-SF) score ≥ 13, indicating moderate-to-severe FCR. * Eastern Cooperative Oncology Group (ECOG) ≤2. * Aware of their diagnosis and willing to participate voluntarily. * Normal cognitive function (Montreal Cognitive Assessment \[MoCA\] score ≥ 26), alert and conscious, and able and willing to communicate their thoughts. Spouse Caregivers: * Identified by the patient as the primary caregiver, providing ≥ 50% of care in the past 2 weeks. * Legally married to the patient. * Age ≥ 22 years for men and ≥ 20 years for women. * Normal cognitive function (MoCA score ≥ 26), no diagnosed mental disorders, able to communicate effectively, and willing to share their thoughts. Exclusion Criteria Patients: * Diagnosed mental disorders or currently receiving psychiatric treatment. * Presence of personality disorders, intellectual disability, memory disorders, brain injury, or neurological disease. * Concurrent malignant tumors in other organs. * Severe complications (e.g., chest pain and/or dyspnea due to pleural tumor invasion). * Spouse caregiver unwilling to participate. * History of upper limb fractures or surgery resulting in impaired hand function. * Participation in other similar psychological interventions. Spouse Caregivers: * Presence of serious comorbid conditions (e.g., respiratory failure, malignant tumors, or other critical illnesses). * Patient unwilling to participate. * Participation in other research studies.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acceptance and commitment therapy are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.